Lilbecep 50mg Injection
Marketer
Eli Lilly and Company India Pvt Ltd
Salt Composition
Epirubicin (50mg)
Overview Lilbecep 50mg Injection
Oncaspar 50mg Injection treats various blood cancers, as well as cancers affecting the breast, stomach, lung, ovaries, and soft tissues. It also aids in preventing bladder cancer relapse post-surgery. Administered intravenously by a healthcare professional, it's used cautiously as a single agent or within combination chemotherapy regimens. Dosage and frequency are determined by your physician based on your condition and may fluctuate. Strict adherence to your prescribed regimen is crucial; misuse or overdose can lead to severe adverse events. Therapeutic effects might not be immediately apparent, requiring several weeks or months; discontinue only under medical guidance. This medication reduces contraceptive effectiveness; reliable birth control is recommended for both partners throughout treatment. Common side effects encompass nausea, thrombocytopenia, alopecia, amenorrhea, pyrexia, and skin rashes. It can lower blood cell counts, increasing infection risk, potentially life-threatening. Regular blood work to monitor blood cell levels, renal, hepatic, and cardiac function is essential during therapy. Prior to commencement, disclose any liver or heart conditions, and provide a complete medication history, as drug interactions can compromise efficacy or alter its mechanism. Disclose pregnancy or breastfeeding to your doctor.
Uses of Lilbecep 50mg Injection
Malignant neoplasm
Major Benefits of Lilbecep 50mg Injection:
This medication will be administered by your physician or registered nurse; please do not attempt self-medication.
Common Side effects of Lilbecep 50mg Injection:
- Low blood platelets
- Nausea
- Hair loss
- Absence of menstrual periods
- Fever
- Anemia (low number of red blood cells)
- Diarrhea
- Weight loss
- Decreased white blood cell count (neutrophils)
- Hot flashes
- Gastrointestinal inflammation
- Rash
- Low energy
- Eye disorder
How to use Lilbecep 50mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
How Lilbecep 50mg Injection works:
Oncaspar 50mg Injection is a drug used in cancer treatment. Its mechanism involves inhibiting topoisomerase II, a crucial enzyme in breast cancer cell DNA replication. This inhibition, coupled with the generation of cytotoxic free radicals, damages the cancer cells' DNA, thus hindering their proliferation and ultimately leading to their demise.
SAFETY ADVICE
AlcoholUNSAFE
Consuming alcohol while using Lilbecep 50mg Injection is inadvisable.
PregnancyCONSULT YOUR DOCTOR
Administering Lilbecep 50mg Injection during gestation poses a confirmed risk to fetal development and is therefore contraindicated. Exceptions may exist in critical circumstances where a physician deems the potential advantages outweigh the inherent dangers. Always seek medical advice.
Breast feedingUNSAFE
Administration of Lilbecep 50mg Injection is contraindicated while breastfeeding due to potential infant toxicity.
DrivingUNSAFE
Administering Lilbecep 50mg Injection may induce adverse reactions that could compromise driving capabilities. Nausea and vomiting, potential side effects of Lilbecep 50mg Injection, may temporarily affect driving ability.
KidneySAFE IF PRESCRIBED
Lilbecep 50mg Injection is likely safe for individuals with impaired kidney function. Current evidence indicates dose modification of Lilbecep 50mg Injection may be unnecessary for this population. However, physician consultation is advised. Reduced dosages might be appropriate for patients exhibiting serum creatinine exceeding 5 mg/dL.
LiverCAUTION
Administering Lilbecep 50mg Injection requires caution for individuals with hepatic impairment; dosage modification may be necessary. Physician consultation is advised. Lilbecep 50mg Injection is contraindicated in patients exhibiting severe liver dysfunction.
What if you forget to take Lilbecep 50mg Injection :
NA
Facts to Know About Lilbecep 50mg Injection
| Label | Value |
|---|---|
| Chemical Type | Anthracycline-based drug |
| Developing Habits | No. |
| Treatment Category | Cancer Drugs |
| Behavior Class | Cytotoxic alkaloids |
3,018 People bought this recently